在接受血造干细胞移植 (HSCT) 的血液性恶性瘤患者中进行同行支持干预:STEPP随机试验试验设计和方法
Emma P Keane1, Michelle Guo2, Lisa M Gudenkauf3
1Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Contemporary clinical trials
|November 20, 2024
概括
这项研究测试了一项通过电话交付的同行支持计划 (STEPP),用于接受血造干细胞移植 (HSCT) 的患者. 这项干预措施有望改善癌症患者的生活质量并减少癌症患者的痛苦.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 心理社会瘤学
背景情况:
- 同行支持干预与癌症护理中患者报告结果 (PRO) 的改善有关.
- 对于接受血造干细胞移植 (HSCT) 的血液性恶性瘤患者的结构化同行支持存在差距.
研究的目的:
- 评估通过电话交付的新型同行支持干预 (STEPP) 的可行性,可接受性和初步有效性.
- 改善生活质量 (QOL) 并减少HSCT患者的心理痛苦.
主要方法:
- 一个单一中心的试点随机临床试验 (RCT) 将支持移植经验与同行计划 (STEPP) 与常规护理进行比较.
- 90名患有血液性恶性瘤的成年患者接受HSCT.
- 可行性基准包括60%的入学率和60%的会议完成率;可接受性通过客户满意度调查问卷来衡量;初步有效性检查了PRO变化.
主要成果:
- 这项研究被注册为NCT06010017.
- 关于招生,完成率,客户满意度和PRO变化的数据正在等待.
结论:
- 这项试点RCT将确定STEPP干预对HSCT患者的可行性,可接受性和初步有效性.
- 这些发现将为未来的全面RCT提供信息,以确定STEPP对患者结果的有效性.
相关概念视频
Bone Marrow Sampling and Transplants
284
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
284
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K


